For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the emergence of Vyndamax and Attruby represents a true advancement . These groundbreaking therapies protect the transthyretin protein, slowing its destructive build-up and reducing the impact of the disease . Individuals are now reporting benefits i… Read More